F Xu 1 , A Gu 1 , Y Ma 1 Show Affiliations »
Abstract
CONTEXT: The 131I activity for treating Graves' disease (GD) is usually determined based on physician's experience. OBJECTIVE: This study aimed to design an empirical method that was not only personalized and quantitative, but also simple, convenient, and easy to grasp. SUBJECTS AND METHODS: The study population comprised patients with GD, selected between May 2013 and May 2016, who received 131I therapy in the Outpatient Department of Shanghai Ninth People's Hospital. The first-visit patients of physician 1 were placed in the traditional group: the activity of 131I (mCi) was calculated using the routine formula: [empirical activity (0.07-0.12 mCi/g) × thyroid mass]/[24-h thyroid 131I uptake]. The first-visit patients of physician 2 were placed in the personalized group. The activity of 131I (mCi) was calculated in two steps. First, the initial activity was calculated: 0.1 mCi/g × thyroid mass (g), and then a personalized and quantitative calibration table of 131I activity was used to obtain a final 131I activity. The cure rate with a single activity of 131I was recorded 1 year later. RESULTS: The traditional and personalized groups included 241 and 282 patients, respectively. Interestingly, the personalized group achieved a higher cure rate [86.5% (244/282) versus 73.4% (177/241), P = 0.000] with a relatively higher 131I activity for the first treatment [8.7 (7, 3.5-30) mCi versus 6.7(6, 2.5-30) mCi, P = 0.000] compared with the traditional group, while the incidence rate of permanent hypothyroidism was not significantly different between the two groups (P = 0.175). CONCLUSION: The empirical method designed in this study was reliable. ©by Acta Endocrinologica Foundation.
CONTEXT: The 131I activity for treating Graves' disease (GD) is usually determined based on physician's experience. OBJECTIVE: This study aimed to design an empirical method that was not only personalized and quantitative, but also simple, convenient, and easy to grasp. SUBJECTS AND METHODS: The study population comprised patients with GD, selected between May 2013 and May 2016, who received 131I therapy in the Outpatient Department of Shanghai Ninth People's Hospital. The first-visit patients of physician 1 were placed in the traditional group: the activity of 131I (mCi) was calculated using the routine formula: [empirical activity (0.07-0.12 mCi/g) × thyroid mass]/[24-h thyroid 131I uptake]. The first-visit patients of physician 2 were placed in the personalized group. The activity of 131I (mCi) was calculated in two steps. First, the initial activity was calculated: 0.1 mCi/g × thyroid mass (g), and then a personalized and quantitative calibration table of 131I activity was used to obtain a final 131I activity. The cure rate with a single activity of 131I was recorded 1 year later. RESULTS: The traditional and personalized groups included 241 and 282 patients, respectively. Interestingly, the personalized group achieved a higher cure rate [86.5% (244/282) versus 73.4% (177/241), P = 0.000] with a relatively higher 131I activity for the first treatment [8.7 (7, 3.5-30) mCi versus 6.7(6, 2.5-30) mCi, P = 0.000] compared with the traditional group, while the incidence rate of permanent hypothyroidism was not significantly different between the two groups (P = 0.175). CONCLUSION: The empirical method designed in this study was reliable. ©by Acta Endocrinologica Foundation.
Entities: Chemical
Keywords:
Graves’ disease; hyperthyroidism; nuclear medicine
Year: 2020
PMID： 33363655 PMCID： PMC7748236 DOI： 10.4183/aeb.2020.329
Source DB: PubMed Journal: Acta Endocrinol (Buchar) ISSN： 1841-0987 Impact factor: 0.877